Nampt/PBEF/visfatin and cancer

Cancer Biology and Therapy

Volumn 10, Issue 2, 2010, Pages 119-125

  Bi, Tie Qiang ^a   Che, Xiang Ming ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer chemotherapy; Carcinogenesis; Clinical trial; DNA damage; Nampt PBEF visfatin; Signaling pathway

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CHS 8282; CYTOKINE; GELATINASE A; GELATINASE B; GMX 1777; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1; INTERLEUKIN 17; MITOGEN ACTIVATED PROTEIN KINASE 3; N [4 (1 BENZOYL 4 PIPERIDINYL)BUTYL] 3 (3 PYRIDINYL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE B; STAT3 PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL MATURATION; CELL MIGRATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SYNTHESIS; FATIGUE; GENE OVEREXPRESSION; GENITAL MUCOSITIS; GENITAL SYSTEM DISEASE; HEAD AND NECK CANCER; HUMAN; NAUSEA; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; THROMBOCYTOPENIA; UPREGULATION; VOMITING;

ACRYLAMIDES; CYTOKINES; DISEASE PROGRESSION; HUMANS; NAD; NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; SIGNAL TRANSDUCTION;

EID: 77955443309     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.2.12581     Document Type: Review

References (75)

1. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007; 23:164-70.
2. Schweiger M, Hennig K, Lerner F, Niere M, Hirsch-Kauffmann M, Specht T, et al. Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis. FEBS Lett 2001; 492:95-100. (Pubitemid 32206727)
3. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14:1431-7.
4. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-30.
5. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Retraction. Science 2007; 318:565.
6. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42.
7. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009; 113:3276-86.
8. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, Kang GB, et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol 2006; 362:66-77. (Pubitemid 44262358)
9. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 2006; 13:582-8.
10. + biosynthetic enzyme. Nat Struct Mol Biol 2006; 13:661-2.
11. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003;544:74-8.
12. + levels dictate cell survival. Cell 2007; 130:1095-107.
13. Garten A, Petzold S, Körner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009; 20:130-8.
14. Gallí M, Van Gool F, Rongvaux A, Andris F, Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation and cancer. Cancer Res 2010; 70:8-11.
15. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008;14:661-73.
16. + salvage pathway by CLOCK-SIRT1. Science 2009; 324:654-7.
17. + biosynthesis. Science 2009; 324:651-4.
18. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyl-transferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279:50754-63.
19. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Drèze PL, Szpirer C, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008;181:4685-95.
20. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 2007; 282:10841-5.
21. Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: Linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta, online.
22. Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP. Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005; 288:486-96.
23. Zhang J. Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked? Bioessays 2003; 25:808-14.
24. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26:882-93.
25. Kolthur-Seetharam U, Dantzer F, McBurney MW, de Murcia G, Sassone-Corsi P. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 2006;5:873-7.
26. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009; 29:4116-29.
27. Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48:9-19.
28. Hufton SE, Moerkerk PT, Brandwijk R, de Bruïne AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999;463:77-82. (Pubitemid 30001722)
29. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruïne AP, Arends JW, Hoogenboom HR, et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 2002; 101:118-27.
30. Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11:7434-43.
31. Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, et al. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 2010; 31:51-7.
32. Bauer L, Venz S, Junker H, Brandt R, Radons J. Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are upregulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1. Int J Oncol 2009; 35:97-107.
33. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006; 580:4105-13.
34. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 2008;7:663-8.
35. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009; 44:685-90.
36. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma and resistin and visfatin for colorectal cancer. Cancer Sci 2010; [Epub ahead of print].
37. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007; 357:150-6.
38. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81:370-80.
39. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signaling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78:356-65.
40. Kim JY, Bae YH, Bae MK, Kim SR, Park HJ, Wee HJ, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta 2009; 1793:1759-67.
41. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, Woo CW, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008; 283:34833-43.
42. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NFkappaB activation in endothelial cells. Biochim Biophys Acta 2008;1783:886-95.
43. Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NFkappaB pathway. Int J Obes (Lond) 2009; 33:465-72.
44. Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 2008; 31:758-60.
45. Martin DS, Schwartz GK. Chemotherapeutically induced DNA Damage, ATP depletion and the apoptotic biochemical cascade. Oncol Res 1997; 9:1-5.
46. Beneke S, Diefenbach J, Bürkle A. Poly(ADP-ribosyl) ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 2004; 111:813-8.
47. Hageman GJ, Stierum RH. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res 2001;475:45-56.
48. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643-9.
49. Nomura F, Yaguchi M, Togawa A, Miyazaki M, Isobe K, Miyake M, et al. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15:529-35.
50. Pedersen PL. The cancer cell's "power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr 2007; 39:1-12.
51. Boritzki TJ, Berry DA, Besserer JA, Cook PD, Fry DW, Leopold WR, et al. Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide). Biochem Pharmacol 1985; 34:1109-14.
52. Pankiewicz KW. Novel nicotinamide adenine dinucleotide analogues as potential anticancer agents: quest for specific inhibition of inosine monophosphate dehydrogenase. Pharmacol Ther 1997; 76:89-100.
53. Berger NA, Berger SJ, Catino DM, Petzold SJ, Robins RK. Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy. J Clin Invest 1985; 75:702-9.
54. Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B, Löser R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res 2002;62:1057-62.
55. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008; 26:45-51.
56. Drevs J, Löser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 2003; 23:4853-8.
57. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 2005;11:3503-13.
58. Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999; 59:5751-7.
59. Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, Sehested M, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008; 367:799-804.
60. Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7.
61. Ekelund S, Larsson R, Nygren P. Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells. Anticancer Res 2002;22:2269-74.
62. Martinsson P, Liminga G, Dhar S, de la Torre M, Lukinius A, Jonsson E, et al. Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. Eur J Cancer 2001;37:260-7.
63. Martinsson P, de la Torre M, Binderup L, Nygren P, Larsson R. Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol 2001; 417:181-7.
64. Martinsson P, Ekelund S, Nygren P, Larsson R. The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro - from cytotoxic synergy to complete inhibition of apoptosis. Br J Pharmacol 2002; 137:568-73.
65. Lövborg H, Martinsson P, Gullbo J, Ekelund S, Nygren P, Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem Pharmacol 2002;63:1491-8.
66. Hansen CM, Hansen D, Holm PK, Larsson R, Binderup L. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. Anticancer Res 2000;20:4211-20.
67. Johanson V, Arvidsson Y, Kölby L, Bernhardt P, Swärd C, Nilsson O, et al. Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice. Neuroendocrinology 2005; 82:171-6.
68. Hassan SB, de la Torre M, Nygren P, Karlsson MO, Larsson R, Jonsson E. A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828. Anticancer Drugs 2001;12:33-42. (Pubitemid 32142281)
69. Aleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Höglund M, Tholander B, et al. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 2001; 12:821-7.
70. Frost BM, Lönnerholm G, Nygren P, Larsson R, Lindhagen E. In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs 2002; 13:735-42.
71. von Heideman A, Berglund A, Larsson R, Nygren P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 2010; 65:1165-72.
72. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, et al. A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 2002; 8:2843-50.
73. Kato H, Ito E, Shi W, Alajez NM, Yue S, Lee C, et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res 2010; 16:898-911.
74. Beauparlant P, Bédard D, Bernier C, Chan H, Gilbert K, Goulet D, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009; 20:346-54.
75. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009;29:5872-88.